Skip to content

Search

New insight into treatment options for rare childhood brain tumour, 2011 Media Release, Telethon Institute for Child Health Research

A new study led by Australian researchers has outlined for the first time the best treatment options for children suffering from meningioma

Telethon Adventurers fund new brain tumour research fellowship

The Telethon Adventurers have announced a new research fellowship to investigate the genes involved in childhood brain tumours.

Perth researchers decipher genetic pattern that predicts leukaemia relapse

Cancer researchers at Perth's The Kids for Child Health Research have discovered a genetic pattern that predicts the likelihood of relapse

Continuing the cancer fight

Work by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.

Apache Energy joins Telethon Institute in cancer research partnership

Apache Energy and the Telethon Institute for Child Health Research today signed a two-year partnership

Adventurers deliver on a promise to help kids with cancer

A state of the art 3D molecular imager that will help researchers monitor how brain tumours grow has been delivered to the Telethon Institute.

New study examines vacccine to prevent cervical cancer

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade

W. Joost Ben Lizeth Rachael Tao Omar Lesterhuis Wylie Orozco Morales Zemek Wang Elaskalani BSc PhD BSc, MSc, PhD BSc (Hons), PhD PhD BSc, MSc, PhD

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

Hematopoietic cell transplantation (HCT) is an effective treatment for pediatric patients with high-risk, refractory, or relapsed acute myeloid leukemia (AML). However, a large proportion of transplanted patients eventually die due to relapse. To improve overall survival, we propose a combined strategy based on cord blood (CB)-HCT with the application of AML-specific T cell receptor (TCR)-engineered T cell therapy derived from the same CB graft.

Exploring Exclusive Breastfeeding and Childhood Cancer Using Linked Data

Citation: Bailey HD. Exploring Exclusive Breastfeeding and Childhood Cancer Using Linked Data. JAMA Netw Open. 2024;7(3):e243075 Keywords: